JP2024504124A5 - - Google Patents
Info
- Publication number
- JP2024504124A5 JP2024504124A5 JP2023543120A JP2023543120A JP2024504124A5 JP 2024504124 A5 JP2024504124 A5 JP 2024504124A5 JP 2023543120 A JP2023543120 A JP 2023543120A JP 2023543120 A JP2023543120 A JP 2023543120A JP 2024504124 A5 JP2024504124 A5 JP 2024504124A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/072397 | 2021-01-18 | ||
| CN2021072397 | 2021-01-18 | ||
| CN2021142043 | 2021-12-28 | ||
| CNPCT/CN2021/142043 | 2021-12-28 | ||
| PCT/CN2022/072297 WO2022152290A1 (en) | 2021-01-18 | 2022-01-17 | Novel anti-gremlin1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504124A JP2024504124A (ja) | 2024-01-30 |
| JP2024504124A5 true JP2024504124A5 (https=) | 2025-01-24 |
| JPWO2022152290A5 JPWO2022152290A5 (https=) | 2025-01-24 |
Family
ID=82446960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543120A Pending JP2024504124A (ja) | 2021-01-18 | 2022-01-17 | 新規の抗グレムリン１抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294622A1 (https=) |
| EP (1) | EP4277927A4 (https=) |
| JP (1) | JP2024504124A (https=) |
| KR (1) | KR20230132544A (https=) |
| CN (1) | CN116848135A (https=) |
| AU (1) | AU2022207030A1 (https=) |
| CA (1) | CA3208455A1 (https=) |
| MX (1) | MX2023008423A (https=) |
| TW (1) | TW202241944A (https=) |
| WO (1) | WO2022152290A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018204A2 (pt) * | 2021-03-11 | 2023-10-24 | Univ Shanghai Jiaotong | Método de tratamento de doenças usando antagonistas de gremlin1 |
| GB202205200D0 (en) * | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| GB202205203D0 (en) * | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| WO2025148900A1 (en) * | 2024-01-08 | 2025-07-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapy of grem1 antagonist and activin receptor antagonist for treating pah |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| ES2898620T3 (es) * | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Anticuerpos humanos contra GREM 1 |
| CN109641954A (zh) * | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| PL3806898T3 (pl) * | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| BR112023018204A2 (pt) * | 2021-03-11 | 2023-10-24 | Univ Shanghai Jiaotong | Método de tratamento de doenças usando antagonistas de gremlin1 |
-
2022
- 2022-01-17 JP JP2023543120A patent/JP2024504124A/ja active Pending
- 2022-01-17 US US18/261,834 patent/US20240294622A1/en active Pending
- 2022-01-17 EP EP22739165.3A patent/EP4277927A4/en active Pending
- 2022-01-17 CA CA3208455A patent/CA3208455A1/en active Pending
- 2022-01-17 WO PCT/CN2022/072297 patent/WO2022152290A1/en not_active Ceased
- 2022-01-17 KR KR1020237027807A patent/KR20230132544A/ko active Pending
- 2022-01-17 CN CN202280010207.XA patent/CN116848135A/zh active Pending
- 2022-01-17 AU AU2022207030A patent/AU2022207030A1/en active Pending
- 2022-01-17 MX MX2023008423A patent/MX2023008423A/es unknown
- 2022-01-18 TW TW111102041A patent/TW202241944A/zh unknown